Breakthrough in Metastatic Prostate Cancer: Sac-TMT + Pembrolizumab Combo Shows Promising Results

Описание: Prostate cancer treatment, metastatic CRPC, sacituzumab tirumotecan, pembrolizumab, phase 2 study results, ESMO Congress 2025.
Dive into the latest findings from a phase 2 clinical trial evaluating the combination of sacituzumab tirumotecan (sac-TMT) and pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (CRPC).
This video covers key data from cohort D of the MK-2870-002/SKB264-II-06 study, presented at the ESMO Congress 2025. Learn about encouraging activity, including PSA50 responses, objective response rates, and disease control rates in patients receiving sac-TMT at 4 mg/kg or 5 mg/kg doses.
We discuss the manageable safety profile, treatment-related adverse events, and how these results support further development of this combo therapy. Understand the trial design, eligibility criteria, and patient demographics.
Whether you're a medical professional, researcher, or interested in oncology advancements, this breakdown highlights potential new options for metastatic prostate cancer patients.
Explore the implications for next-generation hormonal therapies, chemotherapy history, and biomarkers like TROP2 and PD-L1. Stay informed on cutting-edge cancer treatments.